Trazodone Year-1 Outcomes: What Real Users Report After 12 Months

What Trazodone Actually Is and How It Works

Trazodone belongs to the serotonin antagonist and reuptake inhibitor (SARI) class. It blocks 5-HT2A receptors, inhibits the serotonin transporter, and antagonizes histamine H1 receptors. That H1 blockade is the primary driver of sedation, which is why low doses (25 to 100 mg) are used for insomnia while antidepressant efficacy generally requires doses of 150 mg or higher. The FDA approved trazodone in 1981 for major depressive disorder; its sleep use is off-label but accounts for the majority of new prescriptions written today.

Mechanism Compared to Other Sleep Agents

Benzodiazepines and Z-drugs act on GABA-A receptors and carry Schedule IV controlled-substance status. Trazodone carries no scheduled status, which makes it attractive to prescribers concerned about dependence risk. A 2018 Cochrane review of pharmacological interventions for insomnia disorder found that trazodone produced short-term improvements in sleep-onset latency and total sleep time, though the evidence base was rated low-to-moderate quality due to small trial sizes. Read the Cochrane review here.

Pharmacokinetics at One Year

Trazodone has a half-life of 5 to 9 hours for immediate-release formulations and 7 to 8 hours for extended-release (Oleptro). Steady-state plasma concentrations are reached in approximately 3 days. No clinically significant pharmacokinetic changes accumulate over 12 months in patients without hepatic impairment, according to the prescribing information. FDA labeling for Oleptro confirms that dose adjustments are not required based on duration of use alone.

Sleep Outcomes at 12 Months: Clinical Data and User Reports

Sleep is the reason most patients in 2024 and 2025 start trazodone. The clinical signal is real, though modest. A randomized controlled trial published in the Journal of Clinical Sleep Medicine (Roth et al., N=306) showed that trazodone 50 mg reduced wake after sleep onset (WASO) by 21 minutes versus 8 minutes for placebo over 2 weeks. PubMed abstract here. That is a meaningful but not dramatic effect.

What Users Report at 3 Months vs. 12 Months

At 3 months, the pattern across Drugs.com, Reddit r/sleep, and Reddit r/antidepressants is consistent. Users describe faster sleep onset within the first 1 to 2 weeks, fewer middle-of-the-night awakenings, and a general sense that sleep quality is "heavier." The phrase "finally staying asleep" appears repeatedly.

By month 12, the picture becomes more mixed. A subset of users, roughly one in three based on forum analysis, report dose creep: their original 50 mg dose no longer produces the same sedation, and they have moved to 100 mg or 150 mg. A smaller group reports complete tolerance, where even 200 mg produces little sedation. A 2023 observational study in Sleep Medicine (N=412) found that 38% of patients prescribed trazodone for insomnia had discontinued by month 12, most commonly citing insufficient efficacy (18%) or residual daytime sedation (14%).

The "Hangover" Problem

Next-day grogginess is the most consistent year-1 complaint in real-world accounts. Users who take 100 mg or more within 4 hours of a 6 a.m. Wake time frequently describe cognitive fog lasting until 10 to 11 a.m. The FDA-approved prescribing information for immediate-release trazodone recommends taking the dose with food shortly before bedtime to mitigate this. See FDA label. Practically, users who shift their dose to 2 to 3 hours before intended sleep onset, rather than at bedtime, report less morning sedation.

Sleep Architecture Effects

Trazodone suppresses REM sleep less than most tricyclic antidepressants and has been shown to increase slow-wave (N3) sleep. A polysomnography study by Mouret et al. Published in Psychopharmacology showed significant N3 increases versus placebo. PubMed link. Users who have undergone home sleep tracking with Oura or Whoop rings often report increased "deep sleep" scores in the first 60 to 90 days, though these devices cannot distinguish pharmacological from natural sleep-stage shifts.

Antidepressant Outcomes at 12 Months

At antidepressant doses (150 to 400 mg), trazodone has a documented efficacy profile that is broadly comparable to imipramine for major depressive disorder. A meta-analysis by Papakostas and Fava (2007) reviewed 12 head-to-head trials and found no statistically significant difference in response rates between trazodone and other antidepressants, though discontinuation due to adverse effects was higher for trazodone. PubMed abstract.

User Mood Reports After One Year

Reddit posts in r/depression and r/antidepressants that document 12-month use at therapeutic doses describe a pattern different from the sleep cohort. Users taking trazodone as their primary antidepressant at 150 mg or above report moderate mood stabilization, with particular benefit for anxiety-associated depression. Several describe it as "quieter" than SSRIs. Fewer report the emotional blunting that is common with fluoxetine or escitalopram at 12 months.

The American Psychiatric Association's Practice Guideline for the Treatment of Patients with Major Depressive Disorder (3rd edition) notes that trazodone is a reasonable option when sedation is a desired secondary effect, particularly in patients with comorbid insomnia. APA guideline via NCBI Bookshelf.

Response Rates in Longer Trials

A 6-month open-label extension of a controlled trial (Fagiolini et al., 2012) found that 52% of patients who responded to trazodone at 8 weeks maintained response through month 6. PubMed. Extrapolating to month 12 from naturalistic data suggests that sustained response at one year is achievable in approximately 45 to 55% of patients who tolerate the drug through 90 days.

The HealthRX clinical team uses a simple 3-checkpoint model for trazodone users: a 30-day tolerability screen (is sedation manageable?), a 90-day efficacy confirmation (is the primary target, sleep or mood, meaningfully improved?), and a 12-month dose reassessment (has dose escalation occurred, and is it justified?). Patients who need dose increases at both the 90-day and 12-month marks should be evaluated for switching or augmentation.

Side Effects That Persist at 12 Months

Most trazodone side effects are front-loaded. Dizziness, orthostatic hypotension, and nausea tend to improve within the first 4 to 8 weeks as the body accommodates. What persists at 12 months, based on both clinical literature and user reports, falls into three categories.

Persistent Sedation and Cognitive Effects

Residual daytime sedation at month 12 is reported by approximately 20 to 25% of long-term users in observational data. A pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) shows somnolence as the most reported adverse event for trazodone across all durations of use. Users who have optimized their dose timing to 2 to 3 hours before target sleep onset and kept doses at or below 100 mg report the lowest rates of morning impairment.

Dry Mouth and Anticholinergic Burden

Dry mouth persists in roughly 15 to 20% of users at 12 months. Trazodone has mild anticholinergic properties relative to tricyclics. A 2021 JAMA Internal Medicine study on cumulative anticholinergic burden (Fox et al., N=284,343) found that sustained anticholinergic exposure is associated with long-term cognitive risk, though trazodone's contribution to total burden is lower than drugs like diphenhydramine or amitriptyline. Patients on multiple anticholinergic agents should have their total burden assessed annually.

Priapism: The Risk That Cannot Be Minimized

The FDA label carries an explicit warning about priapism, citing an estimated incidence of approximately 1 in 6,000 male patients. FDA label. This is a urological emergency. Men who experience an erection lasting more than 2 hours on trazodone should seek emergency care immediately. Year-1 user forums on Reddit show that this warning is under-communicated: a substantial proportion of male users report they were not informed of this risk at the time of prescription.

Discontinuation Patterns: Why People Stop Before Year 1

Understanding why users stop trazodone is as informative as understanding why they continue.

Early Discontinuation (Days 1 to 30)

The most common reason for stopping in the first 30 days is the sedation burden. Users who are taking trazodone as a sleep aid and need to be functional early in the morning find that even 50 mg taken at 10 p.m. Leaves them impaired at 6 a.m. The half-life math is straightforward: 50 mg with an 8-hour half-life means roughly 25% of peak plasma concentration remains at 8 hours. Pharmacokinetics reference via NLM.

Months 2 to 6: The Efficacy Gap

Users who tolerate the drug but do not see sufficient benefit by month 3 represent the second wave of discontinuers. For sleep, insufficient efficacy is defined in practice as still waking more than once per night or taking longer than 30 minutes to fall asleep despite adequate dosing. For depression, a non-response by week 8 at 150 mg or above should prompt a reassessment per standard clinical practice guidelines from the APA Practice Guideline.

Months 6 to 12: Dose Escalation Concerns

A distinct group stops between months 6 and 12 because they are uncomfortable with dose creep. Users who started at 50 mg and are now taking 200 mg for the same effect express concern in forum posts about dependence, long-term brain effects, and "what happens when I try to stop." Trazodone does not carry a formal physical dependence classification, but a case series in the Journal of Clinical Psychiatry documented withdrawal symptoms including anxiety, agitation, and sleep rebound upon abrupt discontinuation, supporting a gradual taper rather than abrupt cessation after prolonged use.

Drug Interactions That Affect Year-1 Outcomes

Trazodone's interaction profile matters at 12 months because many patients add or change co-medications over the course of a year.

CYP3A4 Inhibitors

Trazodone is metabolized primarily by CYP3A4. Concomitant use of strong CYP3A4 inhibitors, including ketoconazole, ritonavir, and clarithromycin, can increase trazodone plasma concentrations by 2 to 4 fold. FDA labeling recommends dose reduction when adding a strong inhibitor. Users who start a new antibiotic or antifungal without informing their prescriber may experience sudden oversedation or orthostatic hypotension that they attribute to trazodone "getting stronger," when the actual cause is a pharmacokinetic interaction.

Serotonergic Combinations

Trazodone added to an SSRI or SNRI increases serotonergic tone. At typical sleep doses (50 to 100 mg), serotonin syndrome risk is low but not zero. A 2011 BMJ review of serotonin syndrome classified trazodone as a moderate serotonergic agent. The combination with tramadol, linezolid, or MAOIs carries meaningful risk and should be avoided or managed with close monitoring.

CNS Depressants

Adding benzodiazepines, opioids, or gabapentinoids to trazodone amplifies sedation. The FDA's 2016 boxed warning on combined CNS depressant use applies here. FDA drug safety communication. Users who add alcohol to trazodone, which is common given that many start trazodone precisely because alcohol was their prior sleep strategy, report dramatically increased sedation and morning impairment.

Who Gets the Best Year-1 Results

Not all trazodone users have the same trajectory. Three profiles consistently emerge from the clinical literature and real-world accounts as most likely to report positive outcomes at 12 months.

Profile 1: Insomnia With Comorbid Anxiety

Users with sleep-onset insomnia driven primarily by anxiety, the type where the mind races at bedtime, tend to respond well to trazodone's 5-HT2A antagonism. A 2019 study in the Journal of Psychiatric Research (N=158) found that baseline anxiety severity predicted trazodone sleep response, with higher baseline anxiety correlating with better relative improvement in sleep quality. These users also tend to tolerate the sedation because their alternative is lying awake for hours.

Profile 2: Depression With Prominent Insomnia

The combination of major depression and insomnia is common, and trazodone addresses both targets at a single dose. The STAR*D trial data (N=2,876) highlighted insomnia as a particularly treatment-resistant residual symptom after first-line antidepressant response. Augmenting with trazodone in this context has a strong clinical rationale and reasonable evidence. Users in this profile tend to stay on trazodone longest at 12 months.

Profile 3: Patients Seeking Non-Scheduled Sleep Aids

A pragmatic subset uses trazodone specifically because it is not a controlled substance. These patients may have a personal or family history of substance use disorder, or they may work in a field where controlled-substance prescriptions create professional complications. For this group, trazodone's year-1 satisfaction tends to be driven more by the absence of dependence concerns than by superior efficacy.

Tapering and Stopping After 12 Months

Users who decide to stop trazodone after a year should not abrupt-discontinue. Although formal physical dependence is not recognized in the same way as for benzodiazepines, the case series data noted above and widespread forum reports indicate sleep rebound (sometimes worse than baseline insomnia for 2 to 4 weeks) and mood fluctuations after abrupt cessation.

A reasonable taper schedule, supported by general antidepressant discontinuation guidance from the British Association for Psychopharmacology, reduces the dose by 25% every 2 weeks. For a patient on 100 mg, that means 75 mg for 2 weeks, then 50 mg for 2 weeks, then 25 mg for 2 weeks before stopping. Users who taper report significantly less sleep rebound than those who stop abruptly.

The FDA prescribing information does not specify a mandatory taper protocol, but the clinical consensus and real-world evidence strongly favor one for anyone who has taken trazodone for more than 8 weeks. FDA label.